Literature DB >> 21186275

Mechanisms of novel cardioprotective functions of CCN2/CTGF in myocardial ischemia-reperfusion injury.

M Shakil Ahmed1, Jørgen Gravning, Vladimir N Martinov, Thomas G von Lueder, Thor Edvardsen, Gabor Czibik, Ingvild T Moe, Leif E Vinge, Erik Øie, Guro Valen, Håvard Attramadal.   

Abstract

CCN2/connective tissue growth factor (CTGF), a CCN family matricellular protein repressed in healthy hearts after birth, is induced in heart failure of various etiologies. Multiple cellular and biological functions have been assigned to CCN2/CTGF depending on cellular context. However, the functions and mechanisms of action of CCN2/CTGF in the heart as well as its roles in cardiac physiology and pathophysiology remain unknown. Transgenic mice with cardiac-restricted overexpression of CTGF (Tg-CTGF) were generated and compared with nontransgenic littermate control (NLC) mice. Tg-CTGF mice displayed slightly lower cardiac mass and inconspicuous increase of myocardial collagen compared with NLC mice but no evidence of contractile dysfunction. Analysis of the myocardial transcriptome by DNA microarray revealed activation of several distinct gene programs in Tg-CTGF hearts involved in cardioprotection and growth inhibition. Indeed, Tg-CTGF mice subjected to ischemia-reperfusion injury by in situ transient occlusion of the left anterior descending coronary artery in vivo displayed reduced vulnerability with markedly diminished infarct size. These findings were recapitulated in isolated hearts perfused with recombinant human (h)CTGF before the ischemia-reperfusion procedure. Consistently, Tg-CTGF hearts, as well as isolated adult cardiac myocytes exposed to recombinant hCTGF, displayed enhanced phosphorylation and activity of the Akt/p70S6 kinase/GSK-3β salvage kinase pathway and induction of several genes with reported cardioprotective functions. Inhibition of Akt activities also prevented the cardioprotective phenotype of hearts from Tg-CTGF mice. This report provides novel evidence that CTGF confers cardioprotection by salvage phosphokinase signaling leading to inhibition of GSK-3β activities, activation of phospho-SMAD2, and reprogramming of gene expression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21186275     DOI: 10.1152/ajpheart.00604.2010

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  35 in total

1.  Genetic Analysis of Connective Tissue Growth Factor as an Effector of Transforming Growth Factor β Signaling and Cardiac Remodeling.

Authors:  Federica Accornero; Jop H van Berlo; Robert N Correll; John W Elrod; Michelle A Sargent; Allen York; Joseph E Rabinowitz; Andrew Leask; Jeffery D Molkentin
Journal:  Mol Cell Biol       Date:  2015-04-13       Impact factor: 4.272

Review 2.  Extracellular Matrix in Ischemic Heart Disease, Part 4/4: JACC Focus Seminar.

Authors:  Nikolaos G Frangogiannis; Jason C Kovacic
Journal:  J Am Coll Cardiol       Date:  2020-05-05       Impact factor: 24.094

Review 3.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

4.  The C-terminal module IV of connective tissue growth factor, through EGFR/Nox1 signaling, activates the NF-κB pathway and proinflammatory factors in vascular smooth muscle cells.

Authors:  Raúl R Rodrigues-Diez; Ana Belen Garcia-Redondo; Macarena Orejudo; Raquel Rodrigues-Diez; Ana Maria Briones; Enrique Bosch-Panadero; Gyorgy Kery; Janos Pato; Alberto Ortiz; Mercedes Salaices; Jesus Egido; Marta Ruiz-Ortega
Journal:  Antioxid Redox Signal       Date:  2015-01-01       Impact factor: 8.401

Review 5.  The extracellular matrix in myocardial injury, repair, and remodeling.

Authors:  Nikolaos G Frangogiannis
Journal:  J Clin Invest       Date:  2017-05-01       Impact factor: 14.808

6.  Connective tissue growth factor (CCN2) is a matricellular preproprotein controlled by proteolytic activation.

Authors:  Ole Jørgen Kaasbøll; Ashish K Gadicherla; Jian-Hua Wang; Vivi Talstad Monsen; Else Marie Valbjørn Hagelin; Meng-Qiu Dong; Håvard Attramadal
Journal:  J Biol Chem       Date:  2018-09-27       Impact factor: 5.157

Review 7.  Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease.

Authors:  Helena M Kok; Lucas L Falke; Roel Goldschmeding; Tri Q Nguyen
Journal:  Nat Rev Nephrol       Date:  2014-10-14       Impact factor: 28.314

Review 8.  The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis.

Authors:  Sumanth D Prabhu; Nikolaos G Frangogiannis
Journal:  Circ Res       Date:  2016-06-24       Impact factor: 17.367

9.  ERK1/2 directly acts on CTGF/CCN2 expression to mediate myocardial fibrosis in cardiomyopathy caused by mutations in the lamin A/C gene.

Authors:  Maria Chatzifrangkeskou; Caroline Le Dour; Wei Wu; John P Morrow; Leroy C Joseph; Maud Beuvin; Fusako Sera; Shunichi Homma; Nicolas Vignier; Nathalie Mougenot; Gisèle Bonne; Kenneth E Lipson; Howard J Worman; Antoine Muchir
Journal:  Hum Mol Genet       Date:  2016-04-30       Impact factor: 6.150

10.  CCN2 exerts direct cytoprotective actions in adult cardiac myocytes by activation of the PI3-kinase/Akt/GSK-3β signaling pathway.

Authors:  Ingvild Tronstad Moe; Tuyet Anh Pham; Else Marie Valbjørn Hagelin; Mohammad Shakil Ahmed; Håvard Attramadal
Journal:  J Cell Commun Signal       Date:  2012-12-04       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.